UK Concessions Get All The Right Molecules, But Not Necessarily At The Right Prices
Pricewatch UK – April 2019
Price concessions granted by the UK’s Department of Health and Social Care to account for volatility in the generics market are finding the right targets, but struggle to closely match averages in the marketplace, according to the latest figures from market researcher WaveData.
You may also be interested in...
Paracetamol, opioids and non-steroidal anti-inflammatory drugs are among the common medicines that “can do more harm than good” and should not be used for managing chronic primary pain, according to a draft NICE guideline.
Sandoz is seeking an en banc rehearing of a recent appeals court decision that stands to keep its Erelzi biosimilar etanercept rival to Enbrel off the market until 2029 in the US, claiming that the ruling provides a “playbook” for originators to extend patents beyond their legitimate terms.
Eli Lilly has seen sales of its Basaglar insulin glargine hybrid remain static in the second quarter of 2020. However, the company reported total sales for the first half that were up by a tenth compared to the first half of 2019.